Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 24, 2019 - Issue 1
Submit an article Journal homepage
1,484
Views
6
CrossRef citations to date
0
Altmetric
Editorial

What role do pharmaceuticals play in the treatment of Peyronie’s disease and is there a need for new emerging drugs?

U MilenkovicDepartment of Urology, University Hospitals Leuven, Leuven, BelgiumView further author information
,
Mm IlgFaculty of Health, Education, Medicine and Social Care, Medical Technology Research Centre, Anglia Ruskin University, Chelmsford, UKView further author information
,
S CellekFaculty of Health, Education, Medicine and Social Care, Medical Technology Research Centre, Anglia Ruskin University, Chelmsford, UKView further author information
&
M AlbersenDepartment of Urology, University Hospitals Leuven, Leuven, BelgiumCorrespondence[email protected]
View further author information
Pages 1-4 | Received 06 Dec 2018, Accepted 04 Mar 2019, Published online: 19 Mar 2019

References

  • Russo, G. I., Milenkovic, U., Hellstrom, W., et al. Clinical efficacy of injection and mechanical therapy for Peyronie’s disease: a systematic review of the literature. Eur Urol. 2018. DOI:10.1016/j.eururo.2018.07.005.
  • Novo, E., Cannito, S., Paternostro, C, et al. Cellular and molecular mechanisms in liver fibrogenesis. Arch Biochem Biophys. 2014;548:20–37.
  • Parola M, Marra F, Myofibroblast PM. like cells and liver fibrogenesis: emerging concepts in a rapidly moving scenario. Mol Aspects Med. 2008;29:58–66.
  • Fernández, M., Semela, D., Bruix, J et al. Angiogenesis in liver disease. J Hepatol. 2009;50:604–620.
  • Gonzalez-Cadavid NF, Rajfer J. Experimental models of peyronie’s disease. Implications for new therapies. J Sex Med. 2009;6:303–313.
  • Gong R, Rifai A, Tolbert EM, et al. Hepatocyte growth factor modulates matrix metalloproteinases and plasminogen activator/plasmin proteolytic pathways in progressive renal interstitial fibrosis. J Am Soc Nephrol. 2003;14:3047–3060.
  • Davila HH, Magee TR, Zuniga FI, et al. Peyronie’s disease associated with increase in plasminogen activator inhibitor in fibrotic plaque. Urology. 2005;65:645–648.
  • Milenković U, Janky R, Hatzichristodoulou G, et al. Transcriptome-wide analysis of Peyronie’s disease plaques using RNA sequencing uncovers targetable signalling pathways for medical therapy. 2018.
  • Land WG. The Role of Damage-Associated Molecular Patterns (DAMPs) in human diseases: part II: dAMPs as diagnostics, prognostics and therapeutics in clinical medicine. Sultan Qaboos Univ Med J. 2015;15:e157–70.
  • Devine CJJ, Somers KD, Jordan GH, et al. Proposal: trauma as the cause of the peyronie’s lesion. J Urol. 1997;157:285–290.
  • Wynn T.A. Mechanism of fibrosis: therapeutic transplation for fibrotic disease. Nat Med. 2013;18:1028–1040.
  • Milenkovic U, Albersen M, Castiglione F. The mechanisms and potential of stem cell therapy for penile fibrosis. Nat Rev Urol. 2018;1. DOI:10.1038/s41585-018-0109-7.
  • Scannell JW, Blanckley A, Boldon H, et al. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012;11:191–200.
  • Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov. 2011;10:507–519.
  • Wagner BK. The resurgence of phenotypic screening in drug discovery and development. Expert Opin Drug Discov. 2016;11:121–125.
  • Nanthakumar, C. B., Hatley, R.J., Lemma, S.et al. Dissecting fibrosis: therapeutic insights from the small-molecule toolbox. Nat Rev Drug Discov. 2015;14.
  • Moffat JG, Rudolph J, Bailey D. Phenotypic screening in cancer drug discovery - past, present and future. Nat Rev Drug Discov. 2014;13:588–602.
  • Ilg, M. M., Mateus, M., Stebbeds, W.J.et al. Antifibrotic synergy between phosphodiesterase type 5 inhibitors and selective oestrogen receptor modulators in Peyronie’s disease models. Eur Urol. 2018. DOI:10.1016/j.eururo.2018.10.014.
  • Ralph DJ, Brooks MD, Bottazoo GF, et al. The treatment of Peyronie’s disease with tamoxifen. Br J Urol. 1992;648–651.
  • Apaydin, E., Semerci, B., Kefi, A.et al. The use of tamoxifen in the treatment of Peyronie’s disease. Int J Impot Res. 1998;S57.
  • Teloken, C., Rhoden, E.L., Grazziotin, T.M.et al. Tamoxifen versus placebo in the treatment of Peyronie’s disease. J Urol. 1999. DOI:10.1016/S0022-5347(05)68087-1.
  • Chung E, DeYoung L, Brock GB. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J Sex Med. 2011;8:1472–1477.
  • Marshall RP, Simpson JK, Lukey PT. Strategies for biomarker discovery in fibrotic disease. Biochim Biophys Acta - Mol Basis Dis. 2013;1832:1079–1087.
  • Pawłowska E, Bianek-Bodzak A. Imaging modalities and clinical assesment in men affected with Peyronie’s disease. Pol J Radiol. 2011;76:33–37.
  • Subramanian, A., Narayan, R., Corsello, S.M.et al. RESOURCE a next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell. 2017.
  • Mora AL, Rojas M, Pardo A, et al. Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease. Nat Rev Drug Discov. 2017;16:810.
  • Klingberg F, Hinz B, White ES. The myofibroblast matrix: implications for tissue repair and fibrosis. J Pathol. 2013;229:298–309.
  • Pakshir P, Hinz B. The big five in fibrosis: macrophages, myofibroblasts, matrix, mechanics, and miscommunication. Matrix Biol. 2018;68–69:81–93.
  • Hinz B. The extracellular matrix and transforming growth factor-β1: tale of a strained relationship. Matrix Biol. 2015;47:54–65.
  • Teloken, C., Rhoden, E.L., Grazziotin, T.M.et al. Tamoxifen versus placebo in the treatment of Peyronie’s disease. J Urol. 1999;162:2003–2005.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.